RTOG Foundation Newsletter

June 2024

info@rtog.org

In this Issue:

• An interview with the new NRG Oncology Podcast co-hosts
• RTOG 3521 Trial Showcase - Currently enrolling sites!
• The RadComp trial (RTOG 3510) meets patient accrual goal
• NRG-RTOG 0848 Abstract Considered a "Best of ASCO" for 2024
• New Investigator Spotlight: Dr. Austin Sim

The New NRG Oncology Podcast:



An Interview with the Co-hosts

Podcasts continue to climb in popularity across a variety of topics and audience populations worldwide. Recently, NRG Oncology delved into the world of broadcasting with the upcoming launch of their podcast, aimed to reach a broad audience with overview information about clinical trials, crucial information regarding specific studies, and the many areas and moving parts involved in oncology practice, patient participation, and more. These podcast episodes are already in the process of being recorded and edited as the group awaits the launch of this new endeavor.

RTOG Foundation interviewed Dr. Stephen Chun of MD Anderson Cancer Center and Lauren Henke at University Hospitals to learn more about this effort. Drs. Chun and Henke are the co-hosts and co-founders of the NRG Oncology podcast.

RTOG Foundation Trial Showcase:



CHS-007-01/RTOG 3521

The CHS-007-01/RTOG 3521 trial, also known as the ‘TRANSPARENT” study, is currently recruiting sites for eventual patient enrollment onto the trial. This trial is a single-arm study designed to test the drug toripalimab in combination with cisplatin and gemcitabine for patients with recurrent metastatic nasopharyngeal cancer that are also systemic treatment-naïve. This trial is available for patients with both EBV-negative and EBV-positive as well as HPV-negative and HPV-positive disease. 

NRG-RTOG 0848 Abstract Considered a "Best of ASCO" for 2024

NRG Oncology recently reported the results from the radiotherapy randomization, which was the second step of their NRG-RTOG 0848 clinical study comparing adjuvant chemotherapy with or without chemoradiation for patients with resected periampullary pancreatic adenocarcinoma. The trial data did not show that the addition of radiation and chemotherapy to adjuvant systemic therapy improved overall survival (OS) for all patients on the study, however, OS was improved among node-negative patients. OS was essentially the same between treatment arms for node positive patients. The trial data also showed that disease-free survival (DFS) was improved with the addition of radiation and chemotherapy to adjuvant systemic therapy, driven by the DFS improvement in node negative patients.

The RadComp Trial (RTOG 3510) Meets Patient Accrual Goal

New Investigator Spotlight:



Austin Sim, MD, JD